Valuation: ORIC Pharmaceuticals, Inc.

Market Cap 1.17B 1.05B 984M 891M 1.67B 112B 1.68B 11.8B 4.61B 57.9B 4.4B 4.31B 186B P/E 2026 *
-7.45x
P/E 2027 * -6.69x
Enterprise Value 1.17B 1.05B 984M 891M 1.67B 112B 1.68B 11.8B 4.61B 57.9B 4.4B 4.31B 186B EV / Sales 2026 *
-
EV / Sales 2027 * -
Free-Float
98.41%
Yield 2026 *
-
Yield 2027 * -
1 week-4.46%
Current month-15.84%
1 month-2.61%
3 months+9.72%
6 months+13.15%
Current year+45.94%
1 week 9.76
Extreme 9.76
11
1 month 9.76
Extreme 9.76
12.32
3 years 3.7
Extreme 3.7
14.9
5 years 2.2
Extreme 2.2
15.4
Manager TitleAgeSince
Chief Executive Officer 47 07/05/2018
Director of Finance/CFO 52 01/09/2019
Chief Tech/Sci/R&D Officer - 18/08/2025
Director TitleAgeSince
Chairman 68 07/03/2018
Director/Board Member 47 07/05/2018
Director/Board Member 62 01/02/2020
Change 5-day change 1-year change 3-year change Capi.($)
+3.01%-4.46%-14.66%+93.65% 1.17B
-2.01%-7.86%+54.60%+70.97% 70.44B
+3.84%-11.02%+8.59%+58.77% 50.31B
+3.35%+1.42%+11.85%+37.39% 47.51B
+0.77%+1.71%+28.21%+31.94% 42.91B
+2.92%-3.23%+309.22%+469.70% 40.39B
+0.89%-3.17%+9.83%+102.64% 39.69B
+0.06%-1.43%+10.47%+43.27% 30.59B
-2.95%-14.09%+37.94%+1.30% 26.8B
+0.02%-6.27%-12.99%-7.93% 22.36B
Average +0.74%-5.58%+44.30%+90.17% 41.22B
Weighted average by Cap. +0.83%-5.44%+53.63%+95.22%

Financials

2026 *2027 *
Net sales - -
Net income -166M -149M -139M -126M -237M -15.8B -239M -1.67B -653M -8.2B -623M -610M -26.38B -199M -179M -167M -151M -284M -18.96B -286M -2.01B -783M -9.84B -748M -732M -31.65B
Net Debt - -
Projected Income Statement - Annual - ORIC Pharmaceuticals, Inc.
Logo ORIC Pharmaceuticals, Inc.
ORIC Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on improving patients’ lives by Overcoming Resistance In Cancer. The Company is advancing a diverse pipeline of clinical and discovery stage therapies designed to counter resistance mechanisms in cancer by leveraging its expertise within three specific areas: hormone-dependent cancers, precision oncology and key tumor dependencies. The Company's clinical-stage product candidates include ORIC-944, an allosteric inhibitor of the polycomb repressive complex 2 (PRC2) via the EED subunit, being developed for prostate cancer, and ORIC-114, a brain penetrant inhibitor that selectively targets EGFR exon 20, HER2 exon 20 and EGFR atypical mutations, being developed across multiple genetically defined cancers. In addition, the Company is also developing multiple discovery stage precision medicines targeting other hallmark cancer resistance mechanisms. Its out-licensing candidates include ORIC-533 and ORIC-613.
Employees
-
Date Price Change
14/10/26 €10.37 +2.93%
13/10/26 €10.07 -4.50%
12/10/26 €10.55 -1.13%
09/10/26 €10.67 -0.19%
08/10/26 €10.69 +0.14%
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
B
MarketScreener Ratings - ORIC Pharmaceuticals, Inc.
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
16
Last Close Price
11.31USD
Average target price
21.43USD
Spread / Average Target
+89.47%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - ORIC Pharmaceuticals, Inc.